Should I buy or sell PetIQ stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PETQ shares. View PETQ analyst ratings or view top-rated stocks .

What is PetIQ's stock price target for 2024?

4 equities research analysts have issued 12 month price targets for PetIQ's stock. Their PETQ share price targets range from $28.00 to $30.00. On average, they anticipate the company's stock price to reach $29.00 in the next year. This suggests a possible upside of 78.1% from the stock's current price. View analysts price targets for PETQ or view top-rated stocks among Wall Street analysts .

How have PETQ shares performed in 2024?

PetIQ's stock was trading at $19.75 at the start of the year. Since then, PETQ stock has decreased by 17.6% and is now trading at $16.28. View the best growth stocks for 2024 here .

When is PetIQ's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our PETQ earnings forecast .

How were PetIQ's earnings last quarter?

PetIQ, Inc. (NASDAQ:PETQ) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.22. The firm had revenue of $219.93 million for the quarter, compared to analysts' expectations of $189.70 million. PetIQ had a net margin of 0.19% and a trailing twelve-month return on equity of 11.72%.

What ETFs hold PetIQ's stock?

ETFs with the largest weight of PetIQ (NASDAQ:PETQ) stock in their portfolio include ProShares Pet Care ETF (PAWZ) . Invesco Russell 2000 Dynamic Multifactor ETF (OMFS) .

What guidance has PetIQ issued on next quarter's earnings?

PetIQ issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $290.0 million-$310.0 million.

What is Cord Christensen's approval rating as PetIQ's CEO?

10 employees have rated PetIQ Chief Executive Officer Cord Christensen on Glassdoor.com . Cord Christensen has an approval rating of 89% among the company's employees.

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include Micron Technology (MU) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , Exelixis (EXEL) , Intel (INTC) , CVS Health (CVS) , QUALCOMM (QCOM) , Editas Medicine (EDIT) and Gilead Sciences (GILD) .

PetIQ (PETQ) raised $86 million in an initial public offering (IPO) on Friday, July 21st 2017. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

Who are PetIQ's major shareholders?

PetIQ's stock is owned by a variety of retail and institutional investors. Top institutional investors include Nepsis Inc. (3.05%), Allspring Global Investments Holdings LLC (0.48%), Los Angeles Capital Management LLC (0.44%) and Banque Cantonale Vaudoise (0.01%). Insiders that own company stock include Allan Hall, John Newland , Mccord Christensen , Michael A Smith, Michael A Smith , Robert Michael Herrman , Ronald Kennedy , Susan Sholtis and Zvi Glasman. View institutional ownership trends .

How do I buy shares of PetIQ?

Shares of PETQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PETQ

PetIQ (PETQ) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PETQ Stock Alerts

$16.28

+0.25 (+1.56%)

(As of 04/19/2024 ET)

Compare

Today's Range: $15.95
▼
$16.43
50-Day Range: $15.55
▼
$19.04
52-Week Range: $11.26
▼
$22.98

Volume: 162,976 shs
Average Volume: 287,121 shs
Market Capitalization: $479.12 million

P/E Ratio: 271.38
Dividend Yield: N/A
Price Target: $29.00

Get PetIQ alerts:

PetIQ MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 78.1% Upside
$29.00 Price Target
Short Interest: Healthy
6.45% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.89
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 29.79%
From $0.94 to $1.22 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

298th out of 918 stocks

Drugs, Proprietaries, & Sundries Industry

6th out of 7 stocks

3.5

Analyst's Opinion

Consensus Rating
PetIQ has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
PetIQ has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.45% of the float of PetIQ has been sold short.
Short Interest Ratio / Days to Cover
PetIQ has a short interest ratio ("days to cover") of 5.9.
Change versus previous month
Short interest in PetIQ has recently decreased by 9.33%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
PetIQ does not currently pay a dividend.
Dividend Growth
PetIQ does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PETQ.

3.3

News and Social Media Coverage

News Sentiment
PetIQ has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for PetIQ this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for PETQ on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
5 people have added PetIQ to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PetIQ insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.30% of the stock of PetIQ is held by insiders.
Percentage Held by Institutions
94.99% of the stock of PetIQ is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for PetIQ are expected to grow by 29.79% in the coming year, from $0.94 to $1.22 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PetIQ is 271.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 140.45.
Price to Earnings Ratio vs. Sector
The P/E ratio of PetIQ is 271.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 215.55.
Price to Book Value per Share Ratio
PetIQ has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About PetIQ Stock (NASDAQ:PETQ)

PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. It also provides OTC medications and supplies primarily within the flea and tick control, dog dewormers, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dog and cat treats, oral health solutions, stain and odor treatments, and pet nutritional supplements under the PetArmor®, Rocco & Roxie®, VetIQ®, Minties® and Sentry® brands. It provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PurLuv, Rocco & Roxie, Minties, Heart Shield Plus, and TruProfen brand names. In addition, the company operates veterinarian service platform through community clinics, pop-up locations, wellness centers, and permanent locations that offer cost effective and convenient veterinary wellness services, including diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene, and wellness checks; and provides veterinary care services. It operates through veterinarian, retail, and e-commerce channels. PetIQ, Inc. was founded in 2010 and is headquartered in Eagle, Idaho.

PETQ Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PETQ Stock News Headlines

April 18, 2024 | investorplace.com

Unleash Your Portfolio: 3 Pet Stocks Poised to Fetch Big Returns

April 13, 2024 | seekingalpha.com

White Brook Capital Partners Q1 2024 Commentary

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

April 9, 2024 | finance.yahoo.com

There's Been No Shortage Of Growth Recently For PetIQ's (NASDAQ:PETQ) Returns On Capital

April 8, 2024 | finance.yahoo.com

PetIQ (PETQ) Dips More Than Broader Market: What You Should Know

March 14, 2024 | globenewswire.com

PetIQ, Inc. Celebrates Expansion of Minties® Dental Treats Brand With Launch of New Dental Chew for Large-Sized Dogs

March 7, 2024 | globenewswire.com

PetIQ, Inc. Kicks Off Flea & Tick Season With NextStar® Campaign Introducing New Pet Parent Education and Veterinary Support Resources

March 1, 2024 | finance.yahoo.com

PetIQ Full Year 2023 Earnings: EPS: US$0.073 (vs US$1.65 loss in FY 2022)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

February 29, 2024 | finance.yahoo.com

PetIQ, Inc. (NASDAQ:PETQ) Q4 2023 Earnings Call Transcript

February 29, 2024 | seekingalpha.com

PetIQ, Inc. 2023 Q4 - Results - Earnings Call Presentation

February 28, 2024 | markets.businessinsider.com

Here's what to expect from PetIQ A's earnings

February 28, 2024 | sfgate.com

PetIQ: Q4 Earnings Snapshot

February 28, 2024 | finance.yahoo.com

PetIQ Inc (PETQ) Reports Strong Growth in 2023 with Record Net Sales and Cash Flow

February 28, 2024 | globenewswire.com

PetIQ, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | finance.yahoo.com

PETQ Jul 2024 17.500 put

February 26, 2024 | finance.yahoo.com

PETQ Jan 2025 20.000 call

February 23, 2024 | wsj.com

PetIQ Inc. Cl A

February 7, 2024 | finance.yahoo.com

PetIQ, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024

February 6, 2024 | seekingalpha.com

PetIQ: Cost Savings, Higher EBITDA Suggest A Potential Valuation Re-Rate

January 3, 2024 | benzinga.com

PetIQ Stock (NASDAQ:PETQ) Dividends: History, Yield and Dates

December 25, 2023 | finance.yahoo.com

Investors in PetIQ (NASDAQ:PETQ) have seen splendid returns of 106% over the past year

December 22, 2023 | finance.yahoo.com

PETQ or ABT: Which Is the Better Value Stock Right Now?

December 22, 2023 | stockhouse.com

PetIQ, Inc.'s New SENTRY® Portable Calming Diffuser Helps Calm Dogs and Cats During the Busy Holiday Season and Beyond

December 22, 2023 | finance.yahoo.com

Fast-paced Momentum Stock PetIQ (PETQ) Is Still Trading at a Bargain

December 20, 2023 | finance.yahoo.com

PetIQ, Inc.’s New SENTRY® Portable Calming Diffuser Helps Calm Dogs and Cats During the Busy Holiday Season and Beyond

December 20, 2023 | markets.businessinsider.com

Buy Rating for PetIQ Amid Growth Potential in Pet Health Sector

See More Headlines

Receive PETQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PetIQ and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Drugs, proprietaries, & sundries
Sub-Industry: N/A
Current Symbol: NASDAQ:PETQ
CUSIP: N/A
CIK: 1668673
Web: www.petiq.com
Phone: (208) 939-8900
Fax: N/A
Employees: 1,933
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $29.00
High Stock Price Target: $30.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +78.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.06
Trailing P/E Ratio: 271.05
Forward P/E Ratio: 17.30
P/E Growth: N/A
Net Income: $2.13 million
Net Margins: 0.19%
Pretax Margin: 0.21%
Return on Equity: 11.72%
Return on Assets: 3.10%

Debt

Debt-to-Equity Ratio: 1.97
Current Ratio: 2.27
Quick Ratio: 1.43

Sales & Book Value

Annual Sales: $1.10 billion
Price / Sales: 0.43
Cash Flow: $2.74 per share
Price / Cash Flow: 5.94
Book Value: $7.58 per share
Price / Book: 2.15

Miscellaneous

Outstanding Shares: 29,430,000
Free Float: 26,694,000
Market Cap: $478.53 million
Optionable: Optionable
Beta: 1.64

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. McCord Christensen (Age 52)
Chairman of the Board & CEO
Comp: $2M
Mr. Michael A. Smith (Age 46)
President & COO
Comp: $1.34M
Mr. Zvi Glasman (Age 60)
Chief Financial Officer
Comp: $1.06M
Mr. William J. Carter
Executive VP & General Counsel
Mr. John Pearson
Executive Vice President of Services & Manufactured Products

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PETQ Stock Analysis - Frequently Asked Questions

Should I buy or sell PetIQ stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PETQ shares.
View PETQ analyst ratings or view top-rated stocks.
What is PetIQ's stock price target for 2024?: 4 equities research analysts have issued 12 month price targets for PetIQ's stock. Their PETQ share price targets range from $28.00 to $30.00. On average, they anticipate the company's stock price to reach $29.00 in the next year. This suggests a possible upside of 78.1% from the stock's current price.
View analysts price targets for PETQ or view top-rated stocks among Wall Street analysts.
How have PETQ shares performed in 2024?: PetIQ's stock was trading at $19.75 at the start of the year. Since then, PETQ stock has decreased by 17.6% and is now trading at $16.28.
View the best growth stocks for 2024 here.
When is PetIQ's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our PETQ earnings forecast.
How were PetIQ's earnings last quarter?: PetIQ, Inc. (NASDAQ:PETQ) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.22. The firm had revenue of $219.93 million for the quarter, compared to analysts' expectations of $189.70 million. PetIQ had a net margin of 0.19% and a trailing twelve-month return on equity of 11.72%.
What ETFs hold PetIQ's stock?: ETFs with the largest weight of PetIQ (NASDAQ:PETQ) stock in their portfolio include ProShares Pet Care ETF (PAWZ).Invesco Russell 2000 Dynamic Multifactor ETF (OMFS).

What guidance has PetIQ issued on next quarter's earnings?: PetIQ issued an update on its first quarter 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $290.0 million-$310.0 million.
What is Cord Christensen's approval rating as PetIQ's CEO?: 10 employees have rated PetIQ Chief Executive Officer Cord Christensen on Glassdoor.com. Cord Christensen has an approval rating of 89% among the company's employees.
What other stocks do shareholders of PetIQ own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Exelixis (EXEL), Intel (INTC), CVS Health (CVS), QUALCOMM (QCOM), Editas Medicine (EDIT) and Gilead Sciences (GILD).
When did PetIQ IPO?: PetIQ (PETQ) raised $86 million in an initial public offering (IPO) on Friday, July 21st 2017. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.
Who are PetIQ's major shareholders?: PetIQ's stock is owned by a variety of retail and institutional investors. Top institutional investors include Nepsis Inc. (3.05%), Allspring Global Investments Holdings LLC (0.48%), Los Angeles Capital Management LLC (0.44%) and Banque Cantonale Vaudoise (0.01%). Insiders that own company stock include Allan Hall, John Newland, Mccord Christensen, Michael A Smith, Michael A Smith, Robert Michael Herrman, Ronald Kennedy, Susan Sholtis and Zvi Glasman.
View institutional ownership trends.
How do I buy shares of PetIQ?: Shares of PETQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PETQ) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial